Tenderwize
Retour à la recherche

Open-House Biologics Discount Agreements 2025-25 - Aflibercept

Techniker Krankenkasse·Hamburg, Germany·Deadline Nov 29, 2026 · 95 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Open-House-Biologika-Rabattverträge 2025-25 - Aflibercept (ATC: S01LA05; Wirkstärke: 40 mg/ml)

40/100

Score d'opportunité

PromisingLow complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

20 / 100

Facteurs de risque

No estimated contract value or framework maximum is provided, making it difficult to assess business potential.

Structured data marks the tender as EU-funded, but the XML notice states 'no-eu-funds'. This may affect any EU funding...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Strong opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until Nov 2026
  • Supply of Aflibercept (40 mg/ml) pharmaceutical products to TK's insured persons under discount agreements.
  • Contract duration up to 12 months starting 01 December 2025, ending 30 November 2026.
Afficher le résumé complet

This is an Open-House procedure by Techniker Krankenkasse (TK) for discount agreements on the drug Aflibercept (ATC S01LA05, 40 mg/ml). The procedure is not a public procurement under EU directives; contracts are concluded with any qualified pharmaceutical entrepreneur on standardized terms. No estimated value, award criteria, or detailed procurement documents were analyzed. The deadline for submissions is 29 November 2026, but the procedure runs until 30 November 2026.

Risques

No estimated contract value or framework maximum is provided, making it difficult to assess business potential.

Structured data marks the tender as EU-funded, but the XML notice states 'no-eu-funds'. This may affect any EU funding...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as per §4(18) AMG.
  • Must have a valid marketing authorization for the product or be otherwise entitled to market it.

Administrative

  • Must provide a self-declaration on authorization and reliability.

Les exigences peuvent être incomplètes.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open-House Biologics Discount Agreements 2025-25 - Aflibercept

Conclusion of pharmaceutical discount agreements under §130a Abs. 8 SGB V for the active substance Aflibercept (ATC S01LA05, 40 mg/ml) via an open-house procedure. No exclusivity; uniform conditions apply.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

Nov 2025 - Nov 2026

Catégorie

Pharmaceutical products

Date limite

Deadline Nov 29, 2026

Détails de la procédure

Date de publication
04 Jun 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
386710-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3